|
1
|
Walker S: Updates in non-small cell lung
cancer. Clin J Oncol Nurs. 12:587–596. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gong HC, Wang S, Mayer G, et al:
Signatures of drug sensitivity in nonsmall cell lung cancer. Int J
Proteomics. August 7–2011.(Epub ahead of print). View Article : Google Scholar
|
|
3
|
Ramalingam S and Belani CP: Recent
advances in targeted therapy for non-small cell lung cancer. Expert
Opin Ther Targets. 11:245–257. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ambros V: microRNAs: tiny regulators with
great potential. Cell. 107:823–826. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ceppi P, Mudduluru G, Kumarswamy R, et al:
Loss of miR-200c expression induces an aggressive, invasive and
chemoresistant phenotype in non-small cell lung cancer. Mol Cancer
Res. 8:1207–1216. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Markou A, Tsaroucha EG, Kaklamanis L,
Fotinou M, Georgoulias V and Lianidou ES: Prognostic value of
mature microRNA-21 and microRNA-205 overexpression in non-small
cell lung cancer by quantitative real-time RT-PCR. Clin Chem.
54:1696–1704. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang JG, Wang JJ, Zhao F, Liu Q, Jiang K
and Yang GH: MicroRNA-21 (miR-21) represses tumor suppressor PTEN
and promotes growth and invasion in non-small cell lung cancer
(NSCLC). Clin Chim Acta. 411:846–852. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhu X, Li H, Long L, et al: miR-126
enhances the sensitivity of non-small cell lung cancer cells to
anticancer agents by targeting vascular endothelial growth factor
A. Acta Biochim Biophys Sin (Shanghai). 44:519–526. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shibata S: Chemistry and cancer preventing
activities of ginseng saponins and some related triterpenoid
compounds. J Korean Med Sci. (Suppl 16): S28–S37. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bi WY, Fu BD, Shen HQ, et al: Sulfated
derivative of 20(S)-ginsenoside Rh2 inhibits inflammatory cytokines
through MAPKs and NF-kappa B pathways in LPS-induced RAW264.7
macrophages. Inflammation. 35:1659–1668. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
He L, Lee J, Jang JH, et al: Ginsenoside
Rh2 inhibits osteoclastogenesis through down-regulation of
NF-kappaB, NFATc1 and c-Fos. Bone. 50:1207–1213. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Luo JZ and Luo L: Ginseng on
hyperglycemia: effects and mechanisms. Evid Based Complement
Alternat Med. 6:423–427. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu N, Wu GC, Hu R, Li M and Feng H:
Ginsenoside Rh2 inhibits glioma cell proliferation by targeting
microRNA-128. Acta Pharmacol Sin. 32:345–353. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li B, Zhao J, Wang CZ, et al: Ginsenoside
Rh2 induces apoptosis and paraptosis-like cell death in colorectal
cancer cells through activation of p53. Cancer Lett. 301:185–192.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang C, Yu H and Hou J: Effects of 20
(S)-ginsenoside Rh2 and 20 (R)-ginsenoside Rh2 on proliferation and
apoptosis of human lung adenocarcinoma A549 cells. Zhongguo Zhong
Yao Za Zhi. 36:1670–1674. 2011.(In Chinese).
|
|
16
|
Cheng CC, Yang SM, Huang CY, Chen JC,
Chang WM and Hsu SL: Molecular mechanisms of ginsenoside
Rh2-mediated G1 growth arrest and apoptosis in human lung
adenocarcinoma A549 cells. Cancer Chemother Pharmacol. 55:531–540.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li Q, Li Y, Wang X, et al: Co-treatment
with ginsenoside Rh2 and betulinic acid synergistically induces
apoptosis in human cancer cells in association with enhanced
capsase-8 activation, bax translocation, and cytochrome c
release. Mol Carcinog. 50:760–769. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jia WW, Bu X, Philips D, et al: Rh2, a
compound extracted from ginseng, hypersensitizes
multidrug-resistant tumor cells to chemotherapy. Can J Physiol
Pharmacol. 82:431–437. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hu S, Yu JY, Xiong LJ, Hu CP and Zhang YX:
Research on the mechanism of ginsenoside Rh2 reversing the
resistance of lung adenocarcinoma cells to cisplatin. Zhonghua Yi
Xue Za Zhi. 90:264–268. 2010.(In Chinese).
|
|
20
|
Hummel R, Watson DI, Smith C, et al:
Mir-148a improves response to chemotherapy in sensitive and
resistant oesophageal adenocarcinoma and squamous cell carcinoma
cells. J Gastrointest Surg. 15:429–438. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fujita Y, Kojima K, Ohhashi R, et al:
MiR-148a attenuates paclitaxel resistance of hormone-refractory,
drug-resistant prostate cancer PC3 cells by regulating MSK1
expression. J Biol Chem. 285:19076–19084. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lehmann U, Hasemeier B, Christgen M, et
al: Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human
breast cancer. J Pathol. 214:17–24. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zheng B, Liang L, Wang C, et al:
MicroRNA-148a suppresses tumor cell invasion and metastasis by
downregulating ROCK1 in gastric cancer. Clin Cancer Res.
17:7574–7583. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang H, Li Y, Huang Q, et al: MiR-148a
promotes apoptosis by targeting Bcl-2 in colorectal cancer. Cell
Death Differ. 18:1702–1710. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pillai RS, Bhattacharyya SN and Filipowicz
W: Repression of protein synthesis by miRNAs: how many mechanisms?
Trends Cell Biol. 17:118–126. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yue PY, Mak NK, Cheng YK, et al:
Pharmacogenomics and the Yin/Yang actions of ginseng: anti-tumor,
angiomodulating and steroid-like activities of ginsenosides. Chin
Med. 2:62007. View Article : Google Scholar : PubMed/NCBI
|
